Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I6T-MC-AMBA pediatric ulcerative colitis Omvoh trial
2022-502183-20-00Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of mirikizumab in autoimmune colitis, sponsored by Eli Lilly and Company. Primary endpoint: Percentage of participants with Modified Mayo Score (MMS) clinical remission at Week 52 among the Week 12 clinical responders. Started Feb 2024; status: completed.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-502183-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502183-20-00.